Trump's Bold Move to Equalize U.S. Drug Prices Faces Skepticism
President Donald Trump signed an executive order requiring drugmakers to lower U.S. medicine prices to match other nations. The order, which analysts say is tough to implement, sets price targets for 30 days and threatens tariffs if unmet. Legal challenges are expected due to the order's expansiveness.

President Donald Trump has signed an executive order demanding drugmakers reduce the prices of their medicines in the U.S. to match those in other countries, a move that experts argue presents significant implementation challenges. The order sets price targets for the next 30 days, with promises of further government intervention if companies fail to make 'significant progress' within six months.
Speaking at a press conference, Trump warned of possible tariffs on companies if American prices do not equalize with those abroad. The United States currently pays some of the steepest prices for prescription drugs globally. This attempt follows a stalled effort in Trump's first term, hindered by court rulings.
The order, partly inspired by a personal anecdote about price disparities, also calls on the U.S. Federal Trade Commission to counteract anti-competitive practices among pharmaceutical firms. However, legal experts suggest that certain measures, like importing drugs from other developed nations, face potential legal hurdles. Despite investor uncertainty, shares of major drug companies showed resilience following the announcement.
(With inputs from agencies.)
ALSO READ
Dreams on Hold: Taiwanese Students Caught in U.S. Policy Turmoil
Syria Welcomes Easing of U.S. Sanctions: A Path to Economic Revival
Lee Jae-myung's Diplomatic Challenge: Redefining U.S.-Korea Tariff Talks
Congo Hopes to Secure U.S. Mineral Investment and Peace in the East
Science Exodus: Global Doors Open for U.S. Researchers